country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-148012

Copy Link Print Information

SOP1812

(Synonyms: QN-302)

Customer Review

Based on 1 Customer Validation

SOP1812 (QN-302) is a naphthalene diimide (ND) derivative with anti-tumor activity. SOP1812 binds to quadruplex arrangements (G4s), and down-regulates several cancer gene pathways. SOP1812 shows great affinity to hTERT G4 and HuTel21 G4 with K_D values of 4.9 and 28.4 nM, respectively. SOP1812 can be used for the research of cancer.

For research use only. We do not sell to patients.

Purity: 98.46%
CAS No.: 2546091-70-5
Formula: C₄₅H₅₇N₇O₆
Molecular Weight:791.98

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

SOP1812 Chemical Structure

CAS No.: 2546091-70-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
BXPC-3	GI₅₀	2.6 nM Compound: 11; SOP1812	Antiproliferative activity against human BxPC3 cells assessed as growth inhibition after 96 hrs by SRB assay Antiproliferative activity against human BxPC3 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 32832034]
CAPAN-1	GI₅₀	5.9 nM Compound: 11; SOP1812	Antiproliferative activity against human Capan1 cells assessed as growth inhibition after 96 hrs by SRB assay Antiproliferative activity against human Capan1 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 32832034]
MIA PaCa-2	GI₅₀	1.3 nM Compound: 11; SOP1812	Antiproliferative activity against human MIAPaCa2 cells assessed as growth inhibition after 96 hrs by SRB assay Antiproliferative activity against human MIAPaCa2 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 32832034]
PANC-1	GI₅₀	1.4 nM Compound: 11; SOP1812	Antiproliferative activity against human PANC1 cells assessed as growth inhibition after 96 hrs by SRB assay Antiproliferative activity against human PANC1 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 32832034]

In Vitro

SOP1812 (0-50 nM; 96 h) inhibits the proliferation of many cancer cells^[1].
SOP1812 (0-800 nM; 6-24 h) shows great affinity to hTERT G4 and HuTel21 G4^[1].
SOP1812 (40 nM; 6-24 h) affects Wnt/β-catenin, axon guidance, Hippo, MAPK and Rap1 pathways^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

MIA PaCa-2, PANC-1, Capan-1 and BxPC-3 cell lines
Concentration:

0-50 nM
Incubation Time:

96 hours
Result:

Showed anti-proliferation ability to MIA PaCa-2, PANC-1, Capan-1 and BxPC-3 cells with GI₅₀ values of 1.3, 1.4, 5.9 and 2.6 nM, respectively.

Cell Viability Assay^[1]

Cell Line:

PANC-1 cells
Concentration:

0, 100, 400 and 800 nM
Incubation Time:

6 and 24 hours
Result:

Binded to hTERT G4 and HuTel21 G4 with K_D values of 4.9 and 28.4 nM, respectively.

Cell Viability Assay^[1]

Cell Line:

MIA PaCa-2 Cells
Concentration:

40 nM
Incubation Time:

6 and 24 hours
Result:

Affected WNT5B, DVL1, AXIN and APC2 expression which includes in Wnt/β-catenin pathway and also showed effects on axon guidance, Hippo, MAPK, and Rap1 pathways.

In Vivo

SOP1812 (1 mg/kg; i.v. once or twice per week for 28 days) shows anti-tumor activity in MIA PaCa-2 xenografts mice and KPC mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female athymic nude mice with MIA PaCa-2 xenografts^[1]
Dosage:

1 mg/kg
Administration:

Intravenous injection; 1 mg/kg once or twice per week; for 28 days
Result:

Showed complete tumor regression and no significant tumor regrowth after day 28 on several animals.

Animal Model:

KPC mice with PDAC symptoms^[1]
Dosage:

1 mg/kg
Administration:

Intravenous injection; 1 mg/kg once per week; for 3 weeks
Result:

Significantly extended survival of KPC mice and showed a better effect than gemcitabine.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 2546091-70-5
Appearance Solid
Molecular Weight 791.98
Formula C₄₅H₅₇N₇O₆
Color Brown to reddish brown
SMILES

O=C1C2=CC(NCCN3CCCC3)=C4C(N(CCCN5CCOCC5)C(C6=CC(C7=CC=C(CN8CCCC8)C=C7)=C(C2=C64)C(N1CCCN9CCOCC9)=O)=O)=O
Synonyms

QN-302
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ahmed AA, et al. Asymmetrically Substituted Quadruplex-Binding Naphthalene Diimide Showing Potent Activity in Pancreatic Cancer Models. ACS Med Chem Lett. 2020 Jul 16;11(8):1634-1644. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

SOP1812

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

SOP1812

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

SOP1812 Related Classifications

HY-148012 Related Classifications